Recommended wait time for SOT candidates with a prior history of hematological malignancies

Histology	Survival/relapse data	Time interval to transplant	Additional considerations
Diffuse large B cell lymphoma	Survival is equivalent to age- and sex-matched general population after EFS24 and PFS24 achieved	2 years
Follicular lymphoma	No added mortality when compared with age- and sex-matched general population after EFS24 achieved	2 years
Peripheral T cell lymphoma, NOS	23% relapse within 5 years of EFS24, 78% 5-year survival after EFS24 achieved	2 years
Burkitt lymphoma	0.6% relapse after EFS24 achieved	2 years
Hodgkin lymphoma	10% relapse at 10 years after EFS24 achieved	2 years	PET scan negative patients after initial treatment have a low rate of relapse
Monoclonal B cell lymphocytosis	N/A	No wait time
Chronic lymphocytic leukemia	83% 5-year survival untreated	2 to 3 years after treatment	Consider if in remission with no CLL-IPI scores >4

EFS24: event-free survival at 24 months; PFS24: progression-free survival at 24 months; PET: positron emission tomography.

From: Al-Adra DP, Hammel L, Roberts J, et al. Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement. Am J Transplant 2021; 21:475. https://onlinelibrary.wiley.com/doi/10.1111/ajt.16324. Copyright © 2021 John Wiley & Sons Ltd. Reproduced with permission of John Wiley & Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: [email protected] or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (https://onlinelibrary.wiley.com/).

Graphic 135203 Version 1.0

خرید پکیج

Recommended wait time for SOT candidates with a prior history of hematological malignancies